News Sentiment

VTVT sentiment intelligence

vTv Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 32.88 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 39

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

-1.8% over one week, -6.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

vTv Therapeutics (NASDAQ:VTVT) Stock Price Expected to Rise, BTIG Research Analyst Says

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -1.8% Price digesting
Trend fit Trend inactive -6.2% over four weeks
Fair value 54.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 39
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 9
MarketBeat 4
TradingView 3
simplywall.st 3
The Manila Times 2
dars.gov.et 1
Simply Wall St. 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 17
Analyst action 4
Deals and strategy 2
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-48 of 48
Stock Titan Direct company coverage

Two new vTv hires get 39,500 stock options at $32 a share

vTv Therapeutics granted 39,500 stock options to two new non-executive employees as a material inducement for employment. The options have a weighted average exercise price of $32.00 per share, vest over four years, and have a 10-year term. This aligns with the company's 2026 Ind

Tone
Neutral 50/100
Event
Market update
Published
08 May 2026 15:12
Source
Stock Titan
The Manila Times Direct company coverage

vTv Therapeutics to Participate in Upcoming May Investor Conferences

vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced its participation in two investor conferences in May: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the Alliance Global Partners Healthcare Company Showcase. The company will discuss its

Tone
Positive 64/100
Event
Market update
Published
07 May 2026 12:10
Source
The Manila Times
Stock Titan Direct company coverage

vTv Therapeutics (NASDAQ: VTVT) details 2026 virtual annual meeting, board and pay

vTv Therapeutics is holding its 2026 annual virtual-only meeting on June 10, 2026, where stockholders will vote on electing seven directors and ratifying Ernst & Young LLP as the independent auditor. The proxy statement details the company's governance structure, board compositio

Tone
Neutral 50/100
Event
Market update
Published
29 Apr 2026 04:39
Source
Stock Titan
Market source Direct company coverage

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

Wall Street analysts project a 39.9% upside for vTv Therapeutics (VTVT), with a mean price target of $53.33, despite the stock gaining 5.9% in the past four weeks. While investors often rely on such targets, the article cautions against making investment decisions solely based on

Tone
Positive 71/100
Event
Analyst action
Published
20 Apr 2026 04:09
Source
Market source
Stock Titan Direct company coverage

Millennium entities, Israel A. Englander disclose stakes in vTv Therapeutics (VTVT)

Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an amended Schedule 13G/A, disclosing their beneficial ownership in vTv Therapeutics (VTVT). Integrated Core Strategies (US) LLC holds a 5.0% stake,

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Apr 2026 21:38
Source
Stock Titan
MarketBeat Direct company coverage

vTv Therapeutics Inc. (NASDAQ:VTVT) Receives Average Rating of "Moderate Buy" from Analysts

vTv Therapeutics Inc. (NASDAQ:VTVT) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month target price of $53.00. Institutional ownership in the company has increased recently, with holdings now at 17.51%. The biotechnology company recently report

Tone
Positive 69/100
Event
Analyst action
Published
16 Apr 2026 07:40
Source
MarketBeat